Abstracts tagged "comparative effectiveness and harms and rheumatoid arthritis (RA)"

Abstract Number: 473 • ACR/ARHP Annual Meeting 2017
Medication Utilization Patterns of Rheumatoid Arthritis Patients Receiving Anti-TNF Infusion in Community Rheumatology Practices in the United States: Will Differences in Dosing and Administration Efficiencies between Intravenous Golimumab and Infliximab Have a Cost Impact for Payers?
Sergio Schwartzman¹, Lorie A. Ellis², Dennis Parenti³, Shawn Black³, Stephen Xu⁴, Wayne Langholff⁴ and Shelly Kafka³, ¹Weill Cornell Medical College, New York, NY, ²Janssen HECOR Immunology, Horsham, PA, ³Janssen Scientific Affairs, LLC, Horsham, PA, ⁴Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: AWARE (Comparative and Pragmatic Study of Golimumab IV Versus Infliximab in Rheumatoid Arthritis) is an ongoing Phase 4 comparator study designed to provide a…
Abstract Number: 2529 • ACR/ARHP Annual Meeting 2016
Comparative Effectiveness of Tofacitinib, Biologic Drugs and Traditional Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Marina Machado¹, Cristiano S. Moura², Hassan Behlouli¹, Jeffrey R. Curtis³ and Sasha Bernatsky⁴, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor approved in the USA in November 2012 for the treatment of rheumatoid arthritis (RA). As the…